Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor

Search with Google Search with Bing

Information
Drug Name
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
Description
Entry(CIViC)
11
CIViC
Disease Mutation EL ET ED CS VO TR Pubmed Links
cancer KRAS p.Gly12Cys (p.G12C)
( ENST00000256078.10, ENST00000311936.8, ENST00000556131.2, ENST00000557334.6, ENST00000685328.1, ENST00000686969.1, ENST00000688940.1, ENST00000692768.1, ENST00000693229.1 ) KRAS p.Gly12Cys (p.G12C)
( ENST00000256078.10, ENST00000311936.8, ENST00000556131.2, ENST00000557334.6, ENST00000685328.1, ENST00000686969.1, ENST00000688940.1, ENST00000692768.1, ENST00000693229.1 ) 		D Predictive Supports Sensitivity/Response Somatic 3 26739882 Detail
colorectal cancer KRAS EXON 2 MUTATION KRAS EXON 2 MUTATION B Predictive Supports Resistance Somatic 3 27037411 Detail
lung non-small cell carcinoma BCL2L11 DELETION POLYMORPHISM BCL2L11 DELETION POLYMORPHISM B Predictive Supports Resistance Common Germline 4 22426421 Detail
lung non-small cell carcinoma EGFR OVEREXPRESSION
( ENST00000275493.7 ) EGFR OVEREXPRESSION
( ENST00000275493.7 ) 		B Predictive Supports Sensitivity/Response Somatic 4 22056021 Detail
head and neck squamous cell carcinoma CDKN2A p16 EXPRESSION CDKN2A p16 EXPRESSION B Predictive Does Not Support Resistance Somatic 3 24577117 Detail
colorectal cancer HRAS p.Gly13Asp (p.G13D)
( ENST00000311189.8, ENST00000397594.7, ENST00000397596.6, ENST00000417302.7, ENST00000451590.5 ) HRAS p.Gly13Asp (p.G13D)
( ENST00000311189.8, ENST00000397594.7, ENST00000397596.6, ENST00000417302.7, ENST00000451590.5 ) 		C Predictive Supports Resistance Somatic 3 26561417 Detail
lung non-small cell carcinoma EGFR OVEREXPRESSION
( ENST00000275493.7 ) EGFR OVEREXPRESSION
( ENST00000275493.7 ) 		B Predictive Supports Sensitivity/Response Somatic 3 26439803 Detail
glioblastoma EGFR VIII EGFR VIII B Predictive Supports Sensitivity/Response Somatic 4 16282176 Detail
glioblastoma PTEN EXPRESSION PTEN EXPRESSION B Predictive Supports Sensitivity/Response Somatic 4 16282176 Detail
colorectal cancer KRAS MUTATION KRAS MUTATION D Predictive Supports Sensitivity/Response Somatic 2 21890455 Detail
lung non-small cell carcinoma EGFR AMPLIFICATION
( ENST00000275493.7 ) EGFR AMPLIFICATION
( ENST00000275493.7 ) 		B Predictive Supports Sensitivity/Response Somatic 4 20826716 Detail
Annotation
Description Associated Genes Associated Variants Sensitivity Supported Source Links
Preclinical study to investigate mechanisms of KRA... KRAS KRAS p.Gly12Cys (p.G12C)
( ENST00000256078.10, ENST00000311936.8, ENST00000556131.2, ENST00000557334.6, ENST00000685328.1, ENST00000686969.1, ENST00000688940.1, ENST00000692768.1, ENST00000693229.1 ) KRAS p.Gly12Cys (p.G12C)
( ENST00000256078.10, ENST00000311936.8, ENST00000556131.2, ENST00000557334.6, ENST00000685328.1, ENST00000686969.1, ENST00000688940.1, ENST00000692768.1, ENST00000693229.1 ) 		Sensitivity true CIViC Evidence detail
102 mCRC patients treated with anti-EGFR therapy w... KRAS KRAS EXON 2 MUTATION KRAS EXON 2 MUTATION Resitance or Non-Reponse true CIViC Evidence detail
The BIM (BCL2L11) deletion polymorphism was identi... BCL2L11 BCL2L11 DELETION POLYMORPHISM BCL2L11 DELETION POLYMORPHISM Resitance or Non-Reponse true CIViC Evidence detail
EGFR overexpression was correlated with longer ove... EGFR EGFR OVEREXPRESSION
( ENST00000275493.7 ) EGFR OVEREXPRESSION
( ENST00000275493.7 ) 		Sensitivity true CIViC Evidence detail
In this retrospective analysis of the SPECTRUM tri... CDKN2A CDKN2A p16 EXPRESSION CDKN2A p16 EXPRESSION Resitance or Non-Reponse false CIViC Evidence detail
Case report of a patient with metastatic colorecta... HRAS HRAS p.Gly13Asp (p.G13D)
( ENST00000311189.8, ENST00000397594.7, ENST00000397596.6, ENST00000417302.7, ENST00000451590.5 ) HRAS p.Gly13Asp (p.G13D)
( ENST00000311189.8, ENST00000397594.7, ENST00000397596.6, ENST00000417302.7, ENST00000451590.5 ) 		Resitance or Non-Reponse true CIViC Evidence detail
In this prospective study in 37 patients of whom 3... EGFR EGFR OVEREXPRESSION
( ENST00000275493.7 ) EGFR OVEREXPRESSION
( ENST00000275493.7 ) 		Sensitivity true CIViC Evidence detail
49 patients (26 pretreatment tissues available for... EGFR EGFR VIII EGFR VIII Sensitivity true CIViC Evidence detail
49 patients (26 pretreatment tissues available for... PTEN PTEN EXPRESSION PTEN EXPRESSION Sensitivity true CIViC Evidence detail
TLR9 agonist immunomodulatory oligonucleotide (IMO... KRAS KRAS MUTATION KRAS MUTATION Sensitivity true CIViC Evidence detail
A meta-analysis of EGFR gene copy number as a pred... EGFR EGFR AMPLIFICATION
( ENST00000275493.7 ) EGFR AMPLIFICATION
( ENST00000275493.7 ) 		Sensitivity true CIViC Evidence detail
NCT ID Status Phase Summary Start date Completion date
NCT03727867 Unknown status Phase 3 Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Combined With Early Stereotactic Body Radiation Therapy to the Primary Tumor in Advanced Non-small Cell Lung Cancer June 1, 2019 June 1, 2022